Drug approval and drug effectiveness

Annual Review of Clinical Psychology

Volumn 10, Issue , 2014, Pages 741-766

  Spielmans, Glen I ^a,b   Kirsch, Irving ^c,d  

^a METROPOLITAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

Antidepressant; Antipsychotic; Clinical significance; Food and Drug Administration; Quality of life

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; HALOPERIDOL; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTRALINE; VILAZODONE;

CLINICAL EFFECTIVENESS; DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG LEGISLATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HAMILTON SCALE; HUMAN; META ANALYSIS (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PSYCHOPHARMACOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SUSTAINED RELEASE FORMULATION;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG APPROVAL; HUMANS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84897392137     PISSN: 15485943     EISSN: 15485951     Source Type: Book Series    
DOI: 10.1146/annurev-clinpsy-050212-185533     Document Type: Review

References (129)

1. Alltrials.net 2013. All trials registered, all results reported http://www.alltrials.net/
2. Am. Psychiatr. Assoc. Work Group MajorDepress. Disord. 2010. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. Washington, DC: Am. Psychiatr. Assoc. 3rd ed. http://psychiatryonline.org/ content.aspx?bookid=28§ionid=1667485
3. AstraZeneca. 2000. SeroquelTM (quetiapine). Commercial support team-Technical document (TD004): BPRS meta-Analysis. Anchorage, AK: Law Proj. Psychiatr. Rights. http://psychrights.org/research/Digest/NLPs/Seroquel/ OmnibusMSJExhibit2.pdf
4. Bech P 2005. Social functioning: Should it become an endpoint in trials of antidepressants?CNS Drugs 19:313-24
5. Bellack AS, Green MF, Cook JA, Fenton W, Harvey PD, et al. 2007. Assessment of community functioning in people with schizophrenia and other severemental illnesses: A white paper based on an NIMH-sponsored workshop. Schizophr. Bull. 33:805-22
6. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, et al. 2007. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: Ameta-Analysis of randomized controlled trials. JAMA 297:1683-96
7. Chan AW. 2008. Bias, spin, and misreporting: Time for full access to trial protocols and results. PLoS Med. 5:e230
8. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. 2004. Empirical evidence for selective reporting of outcomes in randomized trials: Comparison of protocols to published articles. JAMA 291:2457-65
9. Chen Y, Yang P, Hung J. 2007. Statistical review and evaluation of desvenlafaxine extended-release for major depressive disorder. NDA 21-992. Washington, DC: FDA
10. Clary C. 2000. Zoloft: PSC update. Pfizer. Document from Motus vs. Pfizer case as cited in Moffat B Elliot C. 2007. Ghost marketing: Pharmaceutical companies and ghostwritten journal articles. Perspect. Biol. Med. 50:18-31
11. Code Fed. Regul. 2013. 21CFR314.126. Washington, DC: FDA. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.126
12. Cohen J. 1988. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Erlbaum. 2nd e.d.
13. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. 2006. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatmentresistant depression. Depress. Anxiety 23:364-72
14. Deacon BJ. 2013. The biomedical model of mental disorder: A critical analysis of its validity, utility, and effects on psychotherapy research. Clin. Psychol. Rev. 33:846-61
15. Dep. Veterans Aff. Manag. Major Depress. Disord.Work. Group. 2009. Clinical practice guideline: Management of major depressive disorder (MDD).Washington, DC: Dep. Veterans Aff., Dep. Defense. http://www. healthquality.va.gov/mdd/MDD-FULL-3c1.pdf
16. Dinh P. 2007. Seroquel SR (quetiapine fumarate): Treatment of schizophrenia. Statistical review and evaluation. NDA 22-047/N000. Washington, DC: FDA. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2007/ 022047Orig1s000StatR.pdf
17. Dinh P, Yang P, Hung HMJ. 2008. Statistical review and evaluation of quetiapine for major depressive disorder. Washington, DC: FDA. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM161917.pdf
18. Dinh P, Yang P, Hung HMJ. 2010. Vilazodone for major depressive disorder. Statistical review and evaluation. NDA 22-567/N000. Washington, DC: FDA. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/022567Orig1s000StatR.pdf
19. Earley A, Lau J, Uhlig K. 2013. Haphazard reporting of deaths in clinical trials: A review of cases of ClinicalTrials. gov records and matched publications-A cross-sectional study. BMJ Open 3:1. doi:10.1136/bmjopen-2012- 001963
20. Edwards JG, Anderson I. 1999. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57:507-33
21. Eli Lilly. 2013. Highlights of prescribing information for Prozac (fluoxetine hydrochloride). Indianapolis, IN: Eli Lilly
22. El-Mallakh RS, Briscoe B 2012. Studies of long-Term use of antidepressants: How should the data from them be interpreted?CNS Drugs 26:97-109
23. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, et al. 2002. Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled randomized clinical trial. J. Am. Acad. Child Adolesc. Psychiatry 41:1205-14
24. Emslie GJ, Rush J, Weinberg WA, Kowatch RA, Hughes CW, et al. 1997. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch. Gen. Psychiatry 54:1031-37
25. Eyding D, Lelgemann M, Grouven U, Harter M, Kromp M, et al. 2010. Reboxetine for acute treatment of major depression: Systematic review andmeta-Analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 341:c4737
26. Food Drug Admin. 1990. Psychopharmacological Drugs Advisory Committee 33rd meeting. Rockville, MD: FDA
27. Food Drug Admin. Cent. Drug Eval. Res. 1977. Guidelines for the clinical evaluation of antidepressant drugs. Washington, DC: FDA. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071299.pdf
28. Food Drug Admin. Cent. Drug Eval. Res. 1991. Statistical and medical reviews of sertraline. Washington, DC: FDA. http://drl.ohsu.edu/cdm/ref/ collection/fdadrug/id/3287
29. Food Drug Admin. Cent. Drug Eval. Res. 1994. Statistical review for nefazodone. Major depressive disorder. Washington, DC: FDA. http://drl.ohsu.edu/ cdm/ref/collection/fdadrug/id/3282
30. Food Drug Admin. Cent. Drug Eval. Res. 1994-1995. Bupropion sustained-release clinical review and related approval documents. Washington DC: FDA. http://drl.ohsu.edu/cdm/ref/collection/fdadrug/id/3280
31. Food Drug Admin. Cent.Drug Eval. Res. 1998. Guidance for industry: Providing clinical evidence of effectiveness for human drugs and biological products. Washingto n, DC: USDHHS, FDA, Cent.Drug Eval. Res., Cent. Biol. Eval. Res. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm078749.pdf
32. Food Drug Admin. Mod. Act. 1997. Public law 105-115. Washington, DC: FDA http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/ FullTextofFDAMAlaw/default.htm#SEC
33. Forest Lab. 2012. December. Highlights of prescribing information for Lexapro (escitalopram oxalate). New York: Forest Lab. http://www.frx.com/pi/ lexapro-pi.pdf
34. Forest Lab. 2013. Highlights of prescribing information for Viibryd (vilazodone hydrochloride). New York: Forest Lab. http://www.frx.com/pi/Viibryd- pi.pdf
35. Franks M, Macritchie KA, Mahmood T, Young AH. 2008. Bouncing back: Is the bipolar rebound phenomenon peculiar to lithiumä retrospective naturalistic study. J. Psychopharmacol. 22:452-56
36. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, et al. 2011. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: An updated meta-Analysis. Ann. Intern. Med. 155:772-85
37. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, et al. 2003. Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review. Lancet 361:653-61
38. GlaxoSmithKline. 2013a. January. Paxil (paroxetine hydrochloride) prescribing information. Research Triangle Park, NC: GlaxoSmithKline. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/020031s067,020710s031. pdf
39. GlaxoSmithKline. 2013b. Wellbutrin SR (bupropion sustained-release) tablets prescribing information. Research Triangle Park, NC: GlaxoSmithKline. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/018644s045, 020358s052lbl.pdf
40. Goodwin FK, Whitham EA, Ghaemi SN 2011. Maintenance treatment study designs in bipolar disorder: Do they demonstrate that atypical neuroleptics (antipsychotics) are mood stabilizers?CNS Drugs 25:819-27
41. Gotzsche PC 2011. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials 12:249
42. Green MF. 2007. Stimulating the development of drug treatments to improve cognition in schizophrenia. Annu. Rev. Clin. Psychol. 3:159-80
43. Green MF, Schooler NR, Kern RS, Frese FJ, Granberry W, et al. 2011. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am. J. Psychiatry 168:400-7
44. Greener MJ, Guest JF 2005. Do antidepressants reduce the burden imposed by depression on employers?CNS Drugs 19:253-64
45. Hamilton M. 1960. A rating scale for depression. J. Neurol. Neurosurg. 23:56-61
46. Healy D. 1999. The three faces of the antidepressants: A critical commentary on the clinical-economic context of diagnosis. J. Nerv. Ment. Dis. 187:174-80
47. Healy D. 2000. The assessment of outcomes in depression: Measures of social functioning. Rev. Contemp. Pharmacother. 11:295-301
48. Healy D, Cattell D. 2003. Interface between authorship, industry and science in the domain of therapeutics. Br. J. Psychiatry 183:22-27
49. Healy D, Whitaker C. 2003. Antidepressants and suicide: Risk-benefit conundrums. J. Psychiatry Neurosci. 28:331-37
50. Hochster HS. 2008. The power of "p": On overpowered clinical trials and "positive" results. Gastrointest. Cancer Res. 2:108-9
51. Howland RH. 2011. Publication bias and outcome reporting bias: Agomelatine as a case example. J. Psychosoc. Nurs. Ment. Health Serv. 49:11-14
52. Hrobjartsson A, Chan AW, Haahr MT, Gotzsche PC, Altman DG. 2005. Selective reporting of positive outcomes in randomised trials-secondary publication: A comparison of protocols with published reports. Ugeskr. Laeger 167:3189-91
53. Huston P, Moher D. 1996. Redundancy, disaggregation, and the integrity of medical research. Lancet 347:1024-26
54. Judge R, Parry MG, Quail D, Jacobson JG. 2002. Discontinuation symptoms: Comparison of brief interruption in fluoxetine and paroxetine treatment. Int. Clin. Psychopharmacol. 17:217-25
55. Junod SW 2012. FDA and Clinical Drug Trials: A Short History.Washington, DC: FDA http://www.fda.gov/%20AboutFDA/WhatWeDo/History/Overviews/ucm304485.htm
56. Jureidini JN, McHenry LB, Mansfield PR. 2008. Clinical trials and drug promotion: Selective reporting of study 329. Int. J. Risk Saf. Med. 20:73-81
57. Kaduszkiewicz H, Zimmerman T, Beck-Bornholdt H, den Bussche H. 2005. Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomised clinical trials. BMJ 331:321
58. Kaymaz N, van Os J, Loonen AJ, Nolen WA. 2008. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: A meta-Analysis of placebocontrolled randomized trials. J. Clin. Psychiatry 69:1423-36
59. Kazdin AE. 2006. Arbitrary metrics: Implications for identifying evidence-based treatments. Am. Psychol. 61:42-49
60. Khan A, Faucett J, Lichtenberg P, Kirsch I, Brown WA. 2012. A systematic review of comparative efficacy of treatments and controls for depression. PLoS ONE 7:e41778
61. Khan A, Redding N, Brown WA. 2008. The persistence of the placebo response in antidepressant clinical trials. J. Psychiatr. Res. 42:791-96
62. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. 2008. Initial severity and antidepressant benefits: A meta-Analysis of data submitted to the Food and Drug Administration. PLoS Med. 5:e45
63. Kirsch I, Moore TJ, Scoboria A, Nicholls SS. 2002. The emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev. Treat. 5
64. Kirsch I, Sapirstein G. 1998. Listening to Prozac but hearing placebo: A meta-Analysis of antidepressant medication. Prev. Treat. 1
65. Kline MD. 1989. Fluoxetine and anorgasmia. Am. J. Psychiatry 146:804-5
66. Laughren TP. 2007a. Recommendation of approval action for Seroquel XR (quetiapine) tablets for the short-Term treatment of schizophrenia. Washington, DC: FDA. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2007/ 022047Orig1s000SumR.pdf
67. Laughren TP. 2007b. Recommendation for approvable action for Symbyax (olanzapine/fluoxetine) for treatment of resistant depression (TRD). Washington, DC: FDA. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/ 021520Orig1s012.pdf
68. Laughren TP, Gobburu J, Temple RJ, Unger EF, Bhattaram A, et al. 2011. Vilazodone: Clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J. Clin. Psychiatry 72:1166-73
69. Leber P. 1998. Approvable action on Forrest [sic] Laboratories Inc NDA 20-822 Celexa (citalopram HBr) for the management of depression. Washington, DC: FDA. http://www.accessdata.fda.gov/drugsatfda-docs/nda/98/020822a-admindocs- corres-P1.pdf
70. Lydiard RB, George MS. 1989. Fluoxetine-related anorgasmy. South. Med. J. 82:933-34
71. Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. 2009. Comparison of registered and published primary outcomes in randomized controlled trials. JAMA 302:977-84
72. Mausbach BT, Bowie CR, Harvey PD, Twamley EW, Goldman SR, et al. 2008. Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia. J. Psychiatr. Res. 42:320-27
73. Mausbach BT, Depp CA, Bowie CR, Harvey PD, McGrath JA, et al. 2011. Sensitivity and specificity of the UCSD Performance-based Skills Assessment (UPSA-B) for identifying functional milestones in schizophrenia. Schizophr. Res. 132:165-70
74. McGauran N, Wieseler B, Kreis J, Schuler YB, Kolsch H, Kaiser T. 2010. Reporting bias in medical research-A narrative review. Trials 11:37
75. MelanderH, Ahlqvist-Rastad J, Meijer G, Beermann B. 2003. Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. BMJ 326:1171-73
76. Merlo-Pich E, Alexander RC, Fava M, Gomeni R. 2010. A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs. Clin. Pharmacol. Ther. 88:634-42
77. Michelson D, Fava M, Amsterdam J, Apter J, Londborg P, et al. 2000. Interruption of selective serotonin reuptake inhibitor treatment: Double-blind placebo-controlled trial. Br. J. Psychiatry 176:363-68
78. Moncrieff J. 2006. Does antipsychotic withdrawal provoke psychosis?Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr. Scand. 114:3-13
79. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. 2001. Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J. Clin. Psychiatry 62(Suppl. 3):10-21
80. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, et al. 1997. SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J. Sex Marital Ther. 23:176-94
81. Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134:382-89
82. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. 2004. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol. 19:271-80
83. Mosholder A. 2001. Statistical review for fluoxetine for pediatric OCD and depression. NDA 18-936. Washington, DC: FDA. http://www. antidepressantsfacts.com/doctor-Emslie-3.pdf
84. Natl. Inst. Health Care Excell. 2004. Depression: Management of depression in primary and secondary care. Clin. Guidel. 23. London: NICE
85. Off. Comm. Food Drugs. 2012. Delegation of authority. A notice by the Food and Drug Administration. Washington, DC: Fed. Regist. http://www. federalregister.gov/articles/2012/09/26/2012-23598/office-of-The-commissioner- of-food-And-drugs-delegation-of-Authority.html
86. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. 2002. National trends in the outpatient treatment of depression. JAMA 287:203-9
87. Olson J. 2009. U doctor scrutinized over drug research. St. Paul Pioneer Press, March 18. http://www.twincities.com/ci-11945154
88. Otto MW, Nierenberg AA. 2002. Assay sensitivity, failed clinical trials, and the conduct of science. Psychother. Psychosom. 71:241-43
89. Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M. 2004. Quality of life assessments in major depressive disorder: A review of the literature. Gen. Hosp. Psychiatry 26:13-17
90. Papanikolaou PN, Churchill R, Wahlbeck K, Ioannidis JP. 2004. Safety reporting in randomized trials of mental health interventions. Am. J. Psychiatry 161:1692-97
91. Patkar AA, Pae C. 2013. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs 27:29-37
92. Pfizer. 2012. December. Zoloft (sertraline hydrochloride) prescribing information. New York: Pfizer. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2013/019839s079,020990s038lbl.pdf
93. Pitrou I, Boutron I, Ahmad N, Ravaud P. 2009. Reporting of safety results in published reports of randomized controlled trials. Arch. Intern. Med. 169:1756-61
94. Poznanski E, Mokros H. 1995. Children's Depression Rating Scale-Revised (CDRS-R). Los Angeles: West. Psychol. Serv
95. Pratt LA, Brody DJ, Gu Q. 2011. Antidepressant use in persons aged 12 and over: United States, 2005-2008. NCHS Data Brief 76. Hyattsville, MD: Natl. Cent. Health Statist
96. Prayle AP, Hurley MN, Smyth AR. 2012. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: Cross sectional study. BMJ 344:d7373
97. Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME. 2012. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Curr. Med. Res. Opin. 28:27-39
98. Reyes MM, Panza KE, Martin A, Bloch MH. 2011. Time-lag bias in trials of pediatric antidepressants: A systematic review and meta-Analysis. J. Am. Acad. Child Adolesc. Psychiatry 50:63-72
99. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. 1998. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol. Psychiatry 44:77-87
100. Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM. 2009. Trial publication after registration in ClinicalTrials.Gov: A cross-sectional analysis. PLoS Med. 6:e1000144
101. Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. 2012. Publication of NIH funded trials registered in ClinicalTrials.gov: Cross sectional analysis. BMJ 344:d7292
102. Rutherford BR, Roose SP. 2013. Amodel of placebo response in antidepressant clinical trials. Am. J. Psychiatry 170:723-33
103. Schneider LS, Nelson JC, Clary CM, Newhouse P, Krishnan KRR. 2004. Sertraline and the Cheshire Cat in geriatric depression/Dr. Schneider and colleagues reply. Am. J. Psychiatry 161:759-61
104. Schulz KF, Altman D G, Moher D, CONSORTGroup. 2010.CONSORT2010 statement: Updated guidelines for reporting parallel group randomised trials. PLoS Med. 7:e1000251
105. Schulz SC. 2000. Efficacy of quetiapine versus haloperidol and placebo in the short-Term treatment of acute schizophrenia. Presented at Am. Psychiatr. Assoc. Annu. Meet., Chicago
106. Schwartz LM, Woloshin S. 2011. Communicating uncertainties about prescription drugs to the public: A national randomized trial. Arch. Intern. Med. 171:1463-68
107. Serretti A, Chiesa A. 2009. Treatment-emergent sexual dysfunction related to antidepressants: Ameta-Analysis. J. Clin. Psychopharmacol. 29:259-66
108. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, et al. 2001. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry 158:131-34
109. Siddiqui O. 2003. Statistical review and evaluation for duloxetine for major depressive disorder. NDA 21-427. Washington, DC: FDA. http://www. accessdata.fda.gov/drugsatfda-docs/nda/2004/021427-s000- Cymbalta-Statr.pdf
110. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. 2013. Adjunctive atypical antipsychotics for major depressive disorder: A meta-Analysis of depression, quality of life, and safety outcomes. PLoS Med. 10:e1001403
111. Spielmans GI, Berman MI, Usitalo AN. 2011. Psychotherapy versus second-generation antidepressants in the treatment of depression: A meta-Analysis. J. Nerv. Ment. Dis. 199:142-49
112. Spielmans GI, Biehn TL, Sawrey DL. 2010. A case study of salami slicing: Pooled analyses of duloxetine for depression. Psychother. Psychosom. 79:97-106
113. Spielmans GI, McFall JP. 2006. A comparative meta-Analysis of clinical global impressions change in antidepressant trials. J. Nerv. Ment. Dis. 194:845-52
114. Spielmans GI, Parry PI. 2010. From evidence-based medicine to marketing-based medicine: Evidence from internal industry documents. J. Bioethical Inq. 7:13-29
115. Temple R, Ellenberg SS. 2000. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann. Intern. Med. 133:455-63
116. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. 2003. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: A meta-Analysis. JAMA 289:210-16
117. Tsai AC, RosenlichtNZ, Jureidini JN, Parry PI, Spielmans GI, Healy D. 2011. Aripiprazole in themaintenance treatment of bipolar disorder: A critical review of the evidence and its dissemination into the scientific literature. PLoS Med. 8:1-13
118. Tumas J 1999. Re: 2 EPS abstracts for APA. Email corresp. http://s.wsj.net/public/resources/documents/WSJ-AstraZeneca-Ex14-090227.pdf
119. Tumas J. 2000. FW: Meta analyses. Email corresp. http://stmedia. startribune.com/documents/Omnibus+ MSJ+Exhibit+4.pdf
120. Tumber MB, Dickersin K. 2005. Publication of clinical trials: Accountability and accessibility. J. Intern. Med. 257:65-77
121. Turner EH. 2013a. How to access and process FDA drug approval packages for use in research. BMJ. 347:f5992. http://www.bmj.com/content/347/bmj.f5992
122. Turner EH. 2013b. Publication bias, with a focus on psychiatry: Causes and solutions. CNS Drugs 27:457-68
123. Turner EH, Knoepflmacher D, Shapley L. 2012. Publication bias in antipsychotic trials: An analysis of efficacy comparing the published literature to the US Food and Drug Administration database. PLoS Med. 9:e1001189
124. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. 2008a. Supplementary appendix Supplement to:Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. 2008;358:252-60. http://www.nejm.org/doi/suppl/10. 1056/NEJMsa065779/suppl-file/nejm-turner-252sa1.pdf
125. Turner EH, MatthewsAM, Linardatos E, Tell RA, Rosenthal R. 2008b. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. 358:252-60
126. Turner EH, Rosenthal R. 2008. Efficacy of antidepressants. BMJ 336:516-17
127. Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, et al. 2002. Does cognitive function improve with quetiapine in comparison to haloperidol?Schizophr. Res. 53:239-48
128. Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. 1997. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch. Gen. Psychiatry 54:49-55
129. Zimmerman M, Galione JN, Attiullah N, Friedman M, Toba C, et al. 2010. Underrecognition of clinically significant side effects in depressed outpatients. J. Clin. Psychiatry 71:484-90.